Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL-or Lp (a) hyperlipoproteinemia: Findings gathered from more than 36,000 …
F Heigl, R Hettich, N Lotz, H Reeg, T Pflederer… - Atherosclerosis …, 2015 - Elsevier
… Author links open overlay panel Franz Heigl a , Reinhard Hettich a , Norbert Lotz a ,
Harduin Reeg a , Tobias Pflederer a , Dirk Osterkorn b , Klaus Osterkorn b , Reinhard Klingel c …
Harduin Reeg a , Tobias Pflederer a , Dirk Osterkorn b , Klaus Osterkorn b , Reinhard Klingel c …
Attenuation correction of myocardial SPECT perfusion images with low-dose CT: evaluation of the method by comparison with perfusion PET
…, A Kammeier, R Hagedorn, N Lotz… - Journal of nuclear …, 2005 - Soc Nuclear Med
In cardiac SPECT, specificity is significantly affected by artifacts due to photon absorption.
As the success of attenuation correction depends mainly on high-quality attenuation maps, …
As the success of attenuation correction depends mainly on high-quality attenuation maps, …
[HTML][HTML] Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp (a)-hyperlipoproteinemia with progressive …
F Heigl, R Hettich, N Lotz, H Reeg… - Clinical research in …, 2015 - ncbi.nlm.nih.gov
Low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a)(Lp (a)) are established causal
risk factors for cardiovascular disease (CVD). Efficacy, safety, and tolerability of lipoprotein …
risk factors for cardiovascular disease (CVD). Efficacy, safety, and tolerability of lipoprotein …
Lipoprotein apheresis in Germany–Still more commonly indicated than implemented. How can patients in need access therapy?
F Heigl, T Pflederer, R Klingel, R Hettich, N Lotz… - Atherosclerosis …, 2019 - Elsevier
Background Although lipid-lowering drugs, especially statins, and recently also PCSK9
inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (…
inhibitors can reduce LDL cholesterol (LDL-C) and decrease the risk for cardiovascular disease (…
Indication and Implementation of Lipidapheresis, Rheopheresis, or Immunoadsorption (Lessons learnt from Germany's largest apheresis center)
F Heigl, R Hettich, N Lotz, H Reeg, B Eder… - Atherosclerosis …, 2009 - Elsevier
Efficient modes of extracorporeal blood purification are available today for apheresis
treatment of progessive atherosclerosis, autoimmune disease, or for improving hemorheology. …
treatment of progessive atherosclerosis, autoimmune disease, or for improving hemorheology. …
Binding of biosynthetic human insulin to erythrocytes of normal and insulin-dependent diabetic subjects: Comparison with pork and human pancreatic insulin
W Bachmann, C Sieger, F Lacher, N Lotz - Diabetes Care, 1981 - Am Diabetes Assoc
Biosynthetic human insulin (BHI) was compared with highly purified human pancreatic and
pork insulin with regard to its ability to bind to erythrocytes of normal and insulin-dependent …
pork insulin with regard to its ability to bind to erythrocytes of normal and insulin-dependent …
Lipidological competence centres and networks: Future perspectives to improve healthcare of patients with disorders of lipid metabolism
…, J Ringel, T David-Walek, R Hettich, N Lotz… - Atherosclerosis …, 2017 - Elsevier
Background Numerous healthcare studies have shown that more than 90% of all patients
with dyslipidaemia are not treated adequately. Objectives The “Deutsche Gesellschaft zur …
with dyslipidaemia are not treated adequately. Objectives The “Deutsche Gesellschaft zur …
Efficiency of human insulin (recombinant DNA) in the treatment of diabetic ketoacidosis and severe nonketoacidotic hyperglycemia
W Bachmann, H Walter, N Lotz, H Mehnert - Diabetes Care, 1982 - Am Diabetes Assoc
Human insulin (recombinant DNA) was compared with pork insulin in the treatment of diabetic
ketoacidosis and severe nonketoacidotic hyperglycemia using a continuous, intravenous, …
ketoacidosis and severe nonketoacidotic hyperglycemia using a continuous, intravenous, …
Human insulin (recombinant DNA) in the treatment of patients with newly diagnosed insulin-dependent diabetes mellitus (IDDM)
N Lotz, W Bachmann, H Mehnert - Diabetes care, 1982 - Am Diabetes Assoc
Human insulin (recombinant DNA) was administered subcutaneously to 16 patients with
newly diagnosed insulin-dependent diabetes mellitus (IDDM), whereas a control group of 11 …
newly diagnosed insulin-dependent diabetes mellitus (IDDM), whereas a control group of 11 …
[HTML][HTML] Klinischer Nutzen der Langzeit-Lipoproteinapherese bei Patienten mit schwerer Hypercholesterinämie oder Lp (a)-Hyperlipoproteinämie und progredienter …
F Heigl, R Hettich, N Lotz, H Reeg, T Pflederer… - Clinical Research in …, 2015 - Springer
Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia
or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease | Clinical …
or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease | Clinical …